aTYR PHARMA INC 8K

aTyr Pharma reported Q1 2026 results, outlined plans for a new Phase 3 efzofitimod trial in pulmonary sarcoidosis and progress in its ILD pipeline, and disclosed a quarter-end cash balance of $68.3 million with a net loss of $10.8 million.

On May 15, 2026, aTyr Pharma, Inc. reported its first quarter 2026 financial results and provided a corporate update, highlighting that it will continue development of its lead candidate efzofitimod in pulmonary sarcoidosis following a Type C meeting with the FDA and plans to submit an IND in June 2026 for a new global Phase 3 trial in chronic, symptomatic pulmonary sarcoidosis patients with restrictive lung disease using FVC as the primary endpoint and KSQ-Lung as a key secondary endpoint. The company also reported that it remains on track to complete enrollment in its Phase 2 EFZO-CONNECT study of efzofitimod in systemic sclerosis-related ILD in the first half of 2026, and noted acceptance of a poster on its preclinical candidate ATYR0101 for presentation at the Extracellular Matrix Pharmacology Congress in June 2026. Financially, aTyr ended the quarter with $68.3 million in cash, cash equivalents, restricted cash and investments, incurred $7.3 million in research and development expenses and $4.1 million in general and administrative expenses, and recorded a net loss attributable to aTyr of $10.8 million for the quarter.

Filing Facts

CIK

1339970

Ticker

-

Form

8K

Source Type

sec

Accession

0001339970-26-000030

Alert Tier

6